About us

Matthew brings to the Board his operational knowledge of Shire and his wealth of international sales, marketing, integration and operational experience in the pharmaceutical sector. He is Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals Inc.

He was the Company’s Chief Executive Officer from March 2003 to June 2008 and is also a former Director of Incyte Corporation. Matthew began his career in international pharmaceuticals with Merck & Co, Inc. in 1974, where he held a wide range of sales, marketing and administrative positions. In 1992, he helped to establish Astra Merck Inc., a joint venture between Merck and Astra AB of Sweden, becoming President and Chief Executive Officer. In 1999, he joined Merck KGaA and established EMD Pharmaceuticals, the company’s US prescription pharmaceutical business. He later served as president of Merck KGaA’s global prescription pharmaceuticals business in Germany.  Matthew holds a degree in Business Management.

Angus brings to his position his operational knowledge of Shire and his extensive finance, risk management, strategic and operational experience in the pharmaceutical sector. He recently held a directorship at the City of London Investment Trust plc. Between 1980 and 1999, he held a number of positions of increasing responsibility at ICI, Zeneca and AstraZeneca PLC, including Vice President, Corporate Finance at AstraZeneca and Group Treasurer at Zeneca. Angus is a Chartered Accountant and is a Fellow of the Association of Corporate Treasurers.

Graham brings to his position a broad range of international finance management and planning, audit, risk management and M&A experience. He was Chief Financial Officer of Bacardi in 2007 and Chief Financial Officer of Allied Domecq plc from 1999 to 2005. Graham is a Fellow of the Chartered Institute of Management Accountants.

David brings to the Board his extensive knowledge and experience in financial reporting, risk management and internal financial controls. He is a Non-executive Director of InterContinental Hotels Group plc.

He was Chairman of Premier Foods plc until September 2010 and held directorships at Camelot Group plc and HMV Group plc. Mr Kappler retired from Cadbury Schweppes plc in April 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of the Trebor Group, where he was Financial Director. David is a Fellow of the Chartered Institute of Management Accountants.

David brings to the Board extensive international sales, marketing, operational and supply chain experience gained in the pharmaceutical sector. He is a Director of Allos Therapeutics, Inc., Jabil Circuit, Inc. and Airgas Inc.

David most recently served as President, Pharmaceuticals at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations. He was also responsible for global manufacturing and global Biologics (vaccines) at GlaxoSmithKline. Prior to that, he was President of GlaxoSmithKline’s US Pharmaceuticals Business and before that SmithKline Beecham’s North American Pharmaceuticals Business. Before joining SmithKline Beecham, David worked for many years at Schering-Plough. David holds a B.A. in biology.

William brings to the Board extensive experience in international sales, marketing, integration and operational experience in the pharmaceutical sector. He is a Director of Biotie Therapies Corp., Roche Holdings Ltd, Chugai Pharmaceutical Co., Ltd and Genentech, Inc. and is a former Director of Crucell N.V.

William worked for many years for Roche; most recently as CEO of their Pharmaceuticals Division and as a member of the Roche Group Corporate Executive Committee. Among his many achievements during his time with Roche, he had significant involvement in the acquisition and privatization of Genentech, he led the integration of Boehringer Mannheim Therapeutics and he played a lead role in the negotiations resulting in Roche becoming a majority owner of Chugai in Japan. William holds a B.A. (Hons).

Dr Ginsburg brings to the Board his clinical medical background in Internal Medicine, Hematology-Oncology, and Medical Genetics, as well as his extensive basic biomedical laboratory research expertise. He is currently James V. Neel Distinguished University Professor of Internal Medicine Human Genetics, and Pediatrics at the University of Michigan and a Howard Hughes Medical Institute Investigator. Dr Ginsburg obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School, before joining the faculty at the University of Michigan. Dr Ginsburg is the recipient of numerous honors and awards, including election to membership in the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

Anne brings to the Board her extensive legal, commercial and remuneration experience.  Anne was most recently Group Director Human Resources at Centrica plc and sat on the Centrica Executive Committee until the end of June 2011. She was also chair of the three Centrica Pension Scheme boards for eight years until end of December 2010.  Following her law degree at Aberdeen University and a post graduate diploma in Human Resources she qualified as a lawyer and has an extensive business career that includes senior management roles at Shell UK, the position of Deputy Director-General of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. She has also held directorships at Northumbrian Water plc and SITA UK. Anne is a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds and a Member of Law Society of Scotland.

Susan brings to the Board her extensive mergers and acquisitions and finance experience. Susan is a Director of Hong Kong listed global skin care company, L’Occitane International S.A.  She has a distinguished global career in investment banking having held senior positions with The First Boston Corporation, Bankers Trust, Barclays de Zoete Wedd and most recently Credit Suisse where she was Chairman of the EMEA Mergers & Acquisitions team until 2009 and continues in a part-time senior advisory capacity.  Susan holds a B.A. in Economics and a MBA.